BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Janssen’s Imbruvica Demonstrates Significant Survival Outcomes In Older Adults

  Primary seven-year data from Janssen’s (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.

  June 6, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Gilead’s Trodelvy Data Leaves Some Questioning Clinical Advantage

  Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology’s annual meeting.

  June 6, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  FDA Approves First Measles Vaccine in Half a Century

  GSK’s MMR vaccine is only the second to be approved in the United States for protection against measles, mumps and rubella. The first, licensed to Merck, was approved in 1971.

  June 6, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Real World Study Demonstrates Consistent Survival for Gilead’s Yescarta Across Race/Ethnicity

  The study revealed that Yescarta was both safe and effective in adult patients regardless of race and ethnicity.

  June 6, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  BioMidwest

  Lilly & Boehringer’s Diabetes Drug Slashes Hospitalization Risk for HF by 50%

  The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.

  June 6, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Positive Data Bolster ImmunityBio’s BLA in Bladder Cancer

  Data presented in bladder and pancreatic cancer at ASCO underscore the company’s vision of using NK cells and T cells to target difficult-to-treat cancers.

  June 6, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  BioNTech/Roche mRNA Therapy for Pancreatic Cancer Inspires Early Optimism

  The early data demonstrated a favorable safety profile and encouraging indications of clinical activity. BNT122 is being developed in multiple solid tumor indications.

  June 6, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Alkermes Plants Oncology Flag at ASCO 22

  Well-known for its neurological drug development programs, Alkermes has firmly planted its flag as an oncology company at ASCO. Alkermes Head of Oncology Jessicca Rege spoke with BioSpace.

  June 6, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  AstraZeneca, Daiichi Sankyo Move the Bar in Metastatic Breast Cancer

  Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.

  June 6, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer’s Ibrance Fails to Significantly Extend Lives of Breast Cancer Patients

  Ibrance, a first-line treatment for ER+, HER2 - metastatic breast cancer, did not improve the overall survival rate in patients. Read on to know more.

  June 6, 2022

   · 

  2 min read

   · 

  Hayley Shasteen